mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors
ConclusionsWe have established a personalized and customizable mRNA-therapeutic approach that effectively targets a plurality of tumor antigens and demonstrated potent anti-tumor response in preclinical brain tumor models. This platform mRNA technology uniquely addresses the challenge of tumor heterogeneity and low antigen burden, two key deficiencies in targeting the classically immunotherapy-resistant CNS malignancies, and possibly other cold tumor types.
Source: Genome Medicine - Category: Genetics & Stem Cells Source Type: research
More News: Allergy & Immunology | Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Cancer Vaccines | Covid Vaccine | COVID-19 | Genetics | Immunotherapy | Medulloblastoma | Neurology | Study | Vaccines